Annual CFO
$388.57 M
+$148.46 M+61.83%
31 December 2023
Summary:
Halozyme Therapeutics annual cash flow from operations is currently $388.57 million, with the most recent change of +$148.46 million (+61.83%) on 31 December 2023. During the last 3 years, it has risen by +$333.12 million (+600.71%). HALO annual CFO is now at all-time high.HALO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$115.38 M
+$59.58 M+106.79%
30 September 2024
Summary:
Halozyme Therapeutics quarterly cash flow from operations is currently $115.38 million, with the most recent change of +$59.58 million (+106.79%) on 30 September 2024. Over the past year, it has dropped by -$17.04 million (-12.87%). HALO quarterly CFO is now -24.71% below its all-time high of $153.25 million, reached on 31 December 2017.HALO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$402.95 M
-$17.04 M-4.06%
30 September 2024
Summary:
Halozyme Therapeutics TTM cash flow from operations is currently $402.95 million, with the most recent change of -$17.04 million (-4.06%) on 30 September 2024. Over the past year, it has increased by +$34.28 million (+9.30%). HALO TTM CFO is now -6.52% below its all-time high of $431.03 million, reached on 31 March 2024.HALO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.8% | -12.9% | +9.3% |
| 3 y3 years | +600.7% | -5.2% | +50.4% |
| 5 y5 years | +885.0% | +489.9% | +933.6% |
HALO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +600.7% | -12.9% | +186.8% | -6.5% | +67.8% |
| 5 y | 5 years | at high | +554.9% | -12.9% | +489.9% | -6.5% | +569.4% |
| alltime | all time | at high | +554.9% | -24.7% | +489.9% | -6.5% | +569.4% |
Halozyme Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $115.38 M(+106.8%) | $402.95 M(-4.1%) |
| June 2024 | - | $55.79 M(-56.9%) | $419.99 M(-2.6%) |
| Mar 2024 | - | $129.43 M(+26.5%) | $431.03 M(+10.9%) |
| Dec 2023 | $388.57 M(+61.8%) | $102.35 M(-22.7%) | $388.57 M(+5.4%) |
| Sept 2023 | - | $132.41 M(+98.1%) | $368.67 M(+20.5%) |
| June 2023 | - | $66.84 M(-23.1%) | $305.89 M(+9.5%) |
| Mar 2023 | - | $86.96 M(+5.5%) | $279.28 M(+16.3%) |
| Dec 2022 | $240.11 M(-19.8%) | $82.45 M(+18.4%) | $240.11 M(-0.0%) |
| Sept 2022 | - | $69.64 M(+73.1%) | $240.17 M(-17.8%) |
| June 2022 | - | $40.23 M(-15.8%) | $292.28 M(+1.2%) |
| Mar 2022 | - | $47.80 M(-42.1%) | $288.94 M(-3.5%) |
| Dec 2021 | $299.44 M(+440.0%) | $82.52 M(-32.2%) | $299.44 M(+11.8%) |
| Sept 2021 | - | $121.74 M(+230.0%) | $267.84 M(+76.0%) |
| June 2021 | - | $36.89 M(-36.7%) | $152.19 M(+28.3%) |
| Mar 2021 | - | $58.30 M(+14.5%) | $118.59 M(+113.9%) |
| Dec 2020 | $55.45 M(-164.9%) | $50.92 M(+736.9%) | $55.45 M(-351.0%) |
| Sept 2020 | - | $6.08 M(+84.7%) | -$22.09 M(-61.8%) |
| June 2020 | - | $3.29 M(-168.0%) | -$57.76 M(-32.7%) |
| Mar 2020 | - | -$4.84 M(-81.8%) | -$85.84 M(+0.5%) |
| Dec 2019 | -$85.42 M(+72.6%) | -$26.63 M(-10.0%) | -$85.42 M(+76.7%) |
| Sept 2019 | - | -$29.59 M(+19.4%) | -$48.34 M(+28.3%) |
| June 2019 | - | -$24.79 M(+460.3%) | -$37.67 M(+18.7%) |
| Mar 2019 | - | -$4.42 M(-142.3%) | -$31.75 M(-35.9%) |
| Dec 2018 | -$49.50 M(-136.9%) | $10.46 M(-155.3%) | -$49.50 M(-153.1%) |
| Sept 2018 | - | -$18.93 M(+0.4%) | $93.29 M(-29.6%) |
| June 2018 | - | -$18.86 M(-15.0%) | $132.47 M(-1.4%) |
| Mar 2018 | - | -$22.18 M(-114.5%) | $134.34 M(+0.2%) |
| Dec 2017 | $134.05 M(-366.1%) | $153.25 M(+656.4%) | $134.05 M(-483.4%) |
| Sept 2017 | - | $20.26 M(-219.2%) | -$34.96 M(-45.3%) |
| June 2017 | - | -$17.00 M(-24.3%) | -$63.97 M(+6.9%) |
| Mar 2017 | - | -$22.46 M(+42.4%) | -$59.82 M(+18.7%) |
| Dec 2016 | -$50.38 M(+35.9%) | -$15.77 M(+80.2%) | -$50.38 M(+1.1%) |
| Sept 2016 | - | -$8.75 M(-31.9%) | -$49.81 M(-14.2%) |
| June 2016 | - | -$12.85 M(-1.4%) | -$58.05 M(+60.1%) |
| Mar 2016 | - | -$13.02 M(-14.3%) | -$36.27 M(-2.2%) |
| Dec 2015 | -$37.08 M(-22.0%) | -$15.20 M(-10.5%) | -$37.08 M(+62.5%) |
| Sept 2015 | - | -$16.98 M(-290.0%) | -$22.82 M(+20.0%) |
| June 2015 | - | $8.94 M(-164.6%) | -$19.02 M(-56.5%) |
| Mar 2015 | - | -$13.84 M(+1373.8%) | -$43.73 M(-8.0%) |
| Dec 2014 | -$47.52 M(-3.7%) | -$939.00 K(-92.9%) | -$47.52 M(-23.1%) |
| Sept 2014 | - | -$13.18 M(-16.4%) | -$61.80 M(+1.3%) |
| June 2014 | - | -$15.77 M(-10.6%) | -$61.03 M(+8.6%) |
| Mar 2014 | - | -$17.63 M(+15.8%) | -$56.22 M(+13.9%) |
| Dec 2013 | -$49.34 M | -$15.22 M(+22.6%) | -$49.34 M(-3.2%) |
| Sept 2013 | - | -$12.41 M(+13.3%) | -$50.99 M(-3.6%) |
| June 2013 | - | -$10.96 M(+1.9%) | -$52.87 M(-5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$10.75 M(-36.3%) | -$55.67 M(-13.4%) |
| Dec 2012 | -$64.28 M(+87.4%) | -$16.87 M(+18.0%) | -$64.28 M(+5.5%) |
| Sept 2012 | - | -$14.30 M(+3.9%) | -$60.91 M(+1.4%) |
| June 2012 | - | -$13.76 M(-28.9%) | -$60.06 M(+41.1%) |
| Mar 2012 | - | -$19.36 M(+43.3%) | -$42.57 M(+24.1%) |
| Dec 2011 | -$34.30 M(-24.4%) | -$13.50 M(+0.4%) | -$34.30 M(+21.8%) |
| Sept 2011 | - | -$13.44 M(-459.6%) | -$28.17 M(+6.9%) |
| June 2011 | - | $3.74 M(-133.7%) | -$26.34 M(-40.0%) |
| Mar 2011 | - | -$11.09 M(+50.4%) | -$43.88 M(-3.3%) |
| Dec 2010 | -$45.39 M(+13.0%) | -$7.38 M(-36.5%) | -$45.39 M(-7.3%) |
| Sept 2010 | - | -$11.62 M(-15.8%) | -$48.98 M(-5.5%) |
| June 2010 | - | -$13.79 M(+9.4%) | -$51.84 M(+5.9%) |
| Mar 2010 | - | -$12.60 M(+14.9%) | -$48.97 M(+22.0%) |
| Dec 2009 | -$40.15 M(+13.5%) | -$10.97 M(-24.3%) | -$40.15 M(+5.0%) |
| Sept 2009 | - | -$14.48 M(+32.6%) | -$38.22 M(+11.2%) |
| June 2009 | - | -$10.92 M(+188.9%) | -$34.36 M(+2.1%) |
| Mar 2009 | - | -$3.78 M(-58.2%) | -$33.64 M(-4.9%) |
| Dec 2008 | -$35.37 M(>+9900.0%) | -$9.04 M(-14.9%) | -$35.37 M(+5.6%) |
| Sept 2008 | - | -$10.62 M(+4.2%) | -$33.51 M(+82.3%) |
| June 2008 | - | -$10.20 M(+85.1%) | -$18.38 M(+55.3%) |
| Mar 2008 | - | -$5.51 M(-23.2%) | -$11.84 M(+7912.9%) |
| Dec 2007 | -$147.70 K(-102.1%) | -$7.17 M(-259.4%) | -$147.70 K(-100.6%) |
| Sept 2007 | - | $4.50 M(-223.2%) | $23.18 M(+46.0%) |
| June 2007 | - | -$3.65 M(-159.1%) | $15.88 M(-1.1%) |
| Mar 2007 | - | $6.18 M(-61.8%) | $16.06 M(+126.8%) |
| Dec 2006 | $7.08 M(-154.5%) | $16.16 M(-677.4%) | $7.08 M(-155.8%) |
| Sept 2006 | - | -$2.80 M(-19.5%) | -$12.68 M(-4.4%) |
| June 2006 | - | -$3.48 M(+24.1%) | -$13.26 M(+4.1%) |
| Mar 2006 | - | -$2.80 M(-22.2%) | -$12.74 M(-2.0%) |
| Dec 2005 | -$13.00 M(+68.4%) | -$3.60 M(+6.6%) | -$13.00 M(+6.5%) |
| Sept 2005 | - | -$3.38 M(+14.3%) | -$12.20 M(+7.4%) |
| June 2005 | - | -$2.96 M(-3.3%) | -$11.36 M(+14.8%) |
| Mar 2005 | - | -$3.06 M(+8.9%) | -$9.90 M(+28.2%) |
| Dec 2004 | -$7.72 M(>+9900.0%) | -$2.81 M(+10.8%) | -$7.72 M(+92.5%) |
| Sept 2004 | - | -$2.53 M(+69.4%) | -$4.01 M(+160.1%) |
| June 2004 | - | -$1.50 M(+70.3%) | -$1.54 M(+170.0%) |
| Mar 2004 | - | -$878.90 K(-197.5%) | -$570.80 K(+1046.2%) |
| Dec 2003 | -$49.70 K(-10.9%) | $901.20 K(-1443.1%) | -$49.80 K(-95.0%) |
| Sept 2003 | - | -$67.10 K(-87.2%) | -$990.50 K(+6.1%) |
| June 2003 | - | -$526.00 K(+47.0%) | -$933.90 K(+132.9%) |
| Mar 2003 | - | -$357.90 K(+806.1%) | -$401.00 K(+619.9%) |
| Dec 2002 | -$55.80 K(+62.2%) | -$39.50 K(+276.2%) | -$55.70 K(+243.8%) |
| Sept 2002 | - | -$10.50 K(-252.2%) | -$16.20 K(+184.2%) |
| June 2002 | - | $6900.00(-154.8%) | -$5700.00(-54.8%) |
| Mar 2002 | - | -$12.60 K | -$12.60 K |
| Dec 2001 | -$34.40 K | - | - |
FAQ
- What is Halozyme Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual CFO year-on-year change?
- What is Halozyme Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly CFO year-on-year change?
- What is Halozyme Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM CFO year-on-year change?
What is Halozyme Therapeutics annual cash flow from operations?
The current annual CFO of HALO is $388.57 M
What is the all time high annual CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash flow from operations is $388.57 M
What is Halozyme Therapeutics annual CFO year-on-year change?
Over the past year, HALO annual cash flow from operations has changed by +$148.46 M (+61.83%)
What is Halozyme Therapeutics quarterly cash flow from operations?
The current quarterly CFO of HALO is $115.38 M
What is the all time high quarterly CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash flow from operations is $153.25 M
What is Halozyme Therapeutics quarterly CFO year-on-year change?
Over the past year, HALO quarterly cash flow from operations has changed by -$17.04 M (-12.87%)
What is Halozyme Therapeutics TTM cash flow from operations?
The current TTM CFO of HALO is $402.95 M
What is the all time high TTM CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cash flow from operations is $431.03 M
What is Halozyme Therapeutics TTM CFO year-on-year change?
Over the past year, HALO TTM cash flow from operations has changed by +$34.28 M (+9.30%)